Shareholders' Equity (Tables)

	Six months ended June 30, 2026
	Number of options			Weighted average exercise price		Weighted average remaining contractual term (in years)		Aggregate intrinsic value
								$ thousands

Outstanding at beginning of year		3,896,722			2.57		3.83		117
Granted		1,494,538			2.61
Exercised		(138,564	)		2.08
Forfeited or expired (*)		(113,445	)		2.65

Outstanding at end of the period		5,139,251			2.59		4.17		934

Options exercisable at end of the period		2,824,381			2.64		3.41		569

Vested and expected to vest		4,626,291			2.60		4.03		863

(*) During the six months ended June 30, 2026, 37,975 of the Company’s stock options expired.

	Six months ended June 30, 2026
	Number of RSUs			Weighted average fair value

Unvested at beginning of year		3,468,848			2.34
Granted		537,289			2.49
Vested		(462,683	)		3.15
Forfeited		(241,761	)		2.40

Unvested at end of period		3,301,693			2.34

	Six months ended June 30
	2026		2025
	$ thousands		$ thousands

Cost of revenues		239		189
Research and development, net		408		278
Sales and Marketing		690		640
General and administrative		1,310		1,092

Total share-based compensation expense		2,647		2,199